Trial Profile
A Study to Evaluate the Safety And Efficacy of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir With or Without Ribavirin (3D ± R) Therapy in Chronic Hepatitis C Genotype 1 Patients With Advanced Fibrosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 May 2016 New trial record
- 17 Apr 2016 Interim results (n = 487) presented at The International Liver Congress™ 2016.